The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Evaluating the prognostic significance of CPCs in AL amyloidosis with next-generation flow cytometry
Efstathios Kastritis, MD, University of Athens School of Medicine, Athens, Greece, highlights findings from a study which used next-generation flow cytometry (NGF) to evaluate the prognostic impact of circulating plasma cells (CPCs) in previously untreated patients with light chain (AL) amyloidosis. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
GSK: Honoraria; Takeda: Honoraria; Pfizer: Honoraria, Research Funding; Genesis Pharma: Honoraria; Janssen: Honoraria, Research Funding; Amgen: Honoraria, Research Funding.
